Open access, Clinical/Translational Cancer Immunotherapy

Observation versus maintenance immunotherapy after PD-1-induced clinical complete response in dMMR/MSI-H colorectal cancer managed non-operatively: a multicenter cohort study

20 de October de 2026 by

CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade

14 de October de 2026 by Wang, X., Chen, T., Wang, Z., Wang, C., Xu, X., Yang, M., Zhang, G., Huang, Y., Liu, H.

Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study

8 de October de 2026 by

Purpose
Adjuvant systemic therapy improves recurrence-free survival in resected high-risk melanoma, but elderly patients remain markedly under-represented in clinical trials; their competing risk of death from other causes needs to be considered. Cons…

Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab

7 de October de 2026 by

Background
CD6 is a promising target in cancer immunotherapy, with preclinical evidence supporting its role in modulating immune responses. This warrants further investigation into current CD6-targeting treatments, which could lead to new anti-tumor t…

Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study

5 de October de 2026 by

Background
Immune checkpoint blockade (ICB) improved survival outcomes for patients with metastatic melanoma. Yet up to 65% of patients experience primary resistance and nearly half of initial responders acquire resistance. The clinical utility of ICB…

Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A)

1 de October de 2026 by Zhang, P., Wang, D., He, W., Zhang, H., Dong, Y., Situ, Y., Wang, M., Zhang, Y., Wei, S., Qiu, B., Huang, Y., Liu, H.

Background
Immune-checkpoint inhibitors (ICIs) plus chemotherapy have demonstrated survival benefits in extensive-stage small cell lung cancer (SCLC). The integration of immunotherapy with concurrent chemoradiotherapy (CCRT) may improve survival outco…

Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death

1 de October de 2026 by Li, J., Liu, M., Wei, C., Zhou, Y., Wen, N., Li, J., Zhao, Q.

Background
Combining immunotherapy with endocrine therapy and/or chemotherapy promotes prognosis in patients with estrogen receptor-positive/HER2-negative (ER+HER2–) breast cancer; however, the unclear underlying mechanisms limit their widesprea…

Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL

28 de September de 2026 by

Background
CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential cli…

AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer

24 de September de 2026 by

Background
Patients with metastatic non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (ES-SCLC) have poor prognosis and survival with current standard of care. Several checkpoint inhibitor combinations have been evaluated cl…

Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses

23 de September de 2026 by

Thymic carcinoma is a rare, aggressive malignancy with limited treatment options. First-line platinum-based chemotherapy yields response rates below 40%, and immune checkpoint inhibitors have shown inconsistent efficacy. Ivonescimab, a programmed cell…